Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies

被引：3

作者：

Kang, Hyangju ^{[1
]}

Kim, Daniel ^{[1
]}

Min, Kyungmin ^{[1
]}

Park, Minhee ^{[1
]}

Kim, Seok-Hyun ^{[2
]}

Sohn, Eun-Ju ^{[1
]}

Choi, Bo-Hwa ^{[1
,5
]}

Hwang, Inhwan ^{[3
,4
]}

机构：

[1] BioApplications Inc, Pohang Technopk Complex, Pohang, South Korea

[2] EyeGene, R&D Ctr, Goyang, South Korea

[3] Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea

[4] Pohang Univ Sci & Technol, Dept Life Sci, 77 Cheongam Ro, Pohang 37673, South Korea

[5] BioApplications Inc, Pohang Technopk Complex,314 Jigok ro, Pohang 37668, South Korea

来源：

CLINICAL AND EXPERIMENTAL VACCINE RESEARCH | 2022年 / 11卷 / 03期

关键词：

SARS-CoV-2; Vaccine; Omicron variant; Nicotiana benthamiana; Recombinant S protein; VACCINE;

D O I：

10.7774/cevr.2022.11.3.285

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Various vaccines have been developed to fight severe acute respiratory syndrome coro-navirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 pandemic. However, new variants of SARS-CoV-2 undermine the effort to fight SARS-CoV-2. Here, we produced S proteins harboring the receptor-binding domain (RBD) of the Omicron variant in plants. Plant-produced S proteins together with adjuvant CIA09A triggered strong immune re-sponses in mice. Antibodies in serum inhibited interaction of recombinant human angiotensin-converting enzyme 2 with RBD of the Omicron variant, but not RBD of other variants. These results suggest that antibodies induced by RBD of the Omicron variant are highly specific for the Omicron RBD, but not for that of other variants.

引用

页码：285 / 289

页数：5

共 22 条

[1] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[2] Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines [J].

Araf, Yusha ;

Akter, Fariya ;

Tang, Yan-dong ;

Fatemi, Rabeya ;

Parvez, Md Sorwer Alam ;

Zheng, Chunfu ;

Hossain, Md Golzar .

JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) :1825-1832

[3] Current advances in the development of SARS-CoV-2 vaccines [J].

Awadasseid, Annoor ;

Wu, Yanling ;

Tanaka, Yoshimasa ;

Zhang, Wen .

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (01) :8-19

[4] Covid-19 Breakthrough Infections in Vaccinated Health Care Workers [J].

Bergwerk, Moriah ;

Gonen, Tal ;

Lustig, Yaniv ;

Amit, Sharon ;

Lipsitch, Marc ;

Cohen, Carmit ;

Mandelboim, Michal ;

Gal Levin, Einav ;

Rubin, Carmit ;

Indenbaum, Victoria ;

Tal, Ilana ;

Zavitan, Malka ;

Zuckerman, Neta ;

Bar-Chaim, Adina ;

Kreiss, Yitshak ;

Regev-Yochay, Gili .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1474-1484

[5] The SARS-CoV-2 Vaccine Pipeline: an Overview [J].

Chen, Wen-Hsiang ;

Strych, Ulrich ;

Hotez, Peter J. ;

Bottazzi, Maria Elena .

CURRENT TROPICAL MEDICINE REPORTS, 2020, 7 (02) :61-64

[6] COVID-19 vaccines: where we stand and challenges ahead [J].

Forni, Guido ;

Mantovani, Alberto .

CELL DEATH AND DIFFERENTIATION, 2021, 28 (02) :626-639

[7]

Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]

[8] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [J].

Haas, Eric J. ;

Angulo, Frederick J. ;

McLaughlin, John M. ;

Anis, Emilia ;

Singer, Shepherd R. ;

Khan, Farid ;

Brooks, Nati ;

Smaja, Meir ;

Mircus, Gabriel ;

Pan, Kaijie ;

Southern, Jo ;

Swerdlow, David L. ;

Jodar, Luis ;

Levy, Yeheskel ;

Alroy-Preis, Sharon .

LANCET, 2021, 397 (10287) :1819-1829

[9] The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic [J].

Hoffmann, Markus ;

Krueger, Nadine ;

Schulz, Sebastian ;

Cossmann, Anne ;

Rocha, Cheila ;

Kempf, Amy ;

Nehlmeier, Inga ;

Graichen, Luise ;

Moldenhauer, Anna-Sophie ;

Winkler, Martin S. ;

Lier, Martin ;

Dopfer-Jablonka, Alexandra ;

Jaeck, Hans-Martin ;

Behrens, Georg M. N. ;

Poehlmann, Stefan .

CELL, 2022, 185 (03) :447-+

[10] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [J].

Hoffmann, Markus ;

Kleine-Weber, Hannah ;

Schroeder, Simon ;

Krueger, Nadine ;

Herrler, Tanja ;

Erichsen, Sandra ;

Schiergens, Tobias S. ;

Herrler, Georg ;

Wu, Nai-Huei ;

Nitsche, Andreas ;

Mueller, Marcel A. ;

Drosten, Christian ;

Poehlmann, Stefan .

CELL, 2020, 181 (02) :271-+

← 1 2 3 →